BACKGROUND: Adipose tissue produces "adipocytokines" of uncertain clinical significance. METHODS: We analyzed the relationships among adiposity, adipocytokines, glycemia, and incident diabetes mellitus in 2356 white and black adults aged 70 to 79 years in the Health, Aging, and Body Composition Study who did not have diabetes at baseline. We measured the levels of adipocytokines adiponectin, leptin, interleukin 6, tumor necrosis factor alpha, and plasminogen activator inhibitor 1. Regional fat area was determined by means of computed tomography. New diabetes was defined as a self-reported diagnosis of diabetes or as a fasting plasma glucose level of 126 mg/dL or greater (>/=7.0 mmol/L) at the second, fourth, or sixth annual examination. RESULTS: A total of 143 participants (14.1 cases per 1000 person-years) developed diabetes across 5 years. Visceral fat area (odds ratio [OR], 1.33; 95% confidence interval [CI], 1.10-1.60 per standard deviation increase) and body mass index (white individuals: OR, 1.65; 95% CI, 1.26-2.15 per standard deviation increase; black individuals: OR, 1.22; 95% CI, 0.99-1.51 per standard deviation increase) independently predicted incident diabetes. Adiponectin, leptin, and plasminogen activator inhibitor 1 attenuated the relationship between adiposity and diabetes. After controlling for body mass index, visceral fat, fasting glucose, fasting insulin, high-density lipoprotein cholesterol, triglycerides, and hypertension at baseline, plasminogen activator inhibitor 1 was the only adipocytokine independently associated with increased odds of diabetes (OR, 1.35; 95% CI, 1.01-1.81). Fasting glucose level at baseline remained a strong predictor of incident diabetes, whereas associations with body mass index and visceral fat were attenuated. CONCLUSIONS: Adipocytokines and glycemia partially account for the relationship between adiposity and risk of type 2 diabetes due to adiposity. Plasminogen activator inhibitor 1 may be a useful predictor of diabetes in addition to measurements of body fat.
BACKGROUND: Adipose tissue produces "adipocytokines" of uncertain clinical significance. METHODS: We analyzed the relationships among adiposity, adipocytokines, glycemia, and incident diabetes mellitus in 2356 white and black adults aged 70 to 79 years in the Health, Aging, and Body Composition Study who did not have diabetes at baseline. We measured the levels of adipocytokines adiponectin, leptin, interleukin 6, tumor necrosis factor alpha, and plasminogen activator inhibitor 1. Regional fat area was determined by means of computed tomography. New diabetes was defined as a self-reported diagnosis of diabetes or as a fasting plasma glucose level of 126 mg/dL or greater (>/=7.0 mmol/L) at the second, fourth, or sixth annual examination. RESULTS: A total of 143 participants (14.1 cases per 1000 person-years) developed diabetes across 5 years. Visceral fat area (odds ratio [OR], 1.33; 95% confidence interval [CI], 1.10-1.60 per standard deviation increase) and body mass index (white individuals: OR, 1.65; 95% CI, 1.26-2.15 per standard deviation increase; black individuals: OR, 1.22; 95% CI, 0.99-1.51 per standard deviation increase) independently predicted incident diabetes. Adiponectin, leptin, and plasminogen activator inhibitor 1 attenuated the relationship between adiposity and diabetes. After controlling for body mass index, visceral fat, fasting glucose, fasting insulin, high-density lipoprotein cholesterol, triglycerides, and hypertension at baseline, plasminogen activator inhibitor 1 was the only adipocytokine independently associated with increased odds of diabetes (OR, 1.35; 95% CI, 1.01-1.81). Fasting glucose level at baseline remained a strong predictor of incident diabetes, whereas associations with body mass index and visceral fat were attenuated. CONCLUSIONS: Adipocytokines and glycemia partially account for the relationship between adiposity and risk of type 2 diabetes due to adiposity. Plasminogen activator inhibitor 1 may be a useful predictor of diabetes in addition to measurements of body fat.
Authors: Kristen G Hairston; Michael Bryer-Ash; Jill M Norris; Steven Haffner; Donald W Bowden; Lynne E Wagenknecht Journal: Sleep Date: 2010-03 Impact factor: 5.849
Authors: Sachin Yende; Derek C Angus; Jingzhong Ding; Anne B Newman; John A Kellum; Rongling Li; Robert E Ferrell; Joseph Zmuda; Stephen B Kritchevsky; Tamara B Harris; Melissa Garcia; Kristine Yaffe; Richard G Wunderink Journal: Am J Respir Crit Care Med Date: 2007-08-29 Impact factor: 21.405
Authors: A J G Hanley; L E Wagenknecht; J M Norris; M Bryer-Ash; Y I Chen; A M Anderson; R Bergman; S M Haffner Journal: Diabetologia Date: 2009-07-31 Impact factor: 10.122
Authors: Joachim H Ix; Christina L Wassel; Glenn M Chertow; Annemarie Koster; Karen C Johnson; Frances A Tylavsky; Jane A Cauley; Steven R Cummings; Tamara B Harris; Michael G Shlipak Journal: J Clin Endocrinol Metab Date: 2009-10-09 Impact factor: 5.958
Authors: Shilpa H Jain; Joseph M Massaro; Udo Hoffmann; Guido A Rosito; Ramachandran S Vasan; Annaswamy Raji; Christopher J O'Donnell; James B Meigs; Caroline S Fox Journal: Diabetes Care Date: 2009-02-17 Impact factor: 19.112
Authors: Kristen G Hairston; Ann Scherzinger; Capri Foy; Anthony J Hanley; Orita McCorkle; Steven Haffner; Jill M Norris; Michael Bryer-Ash; Lynne E Wagenknecht Journal: Diabetes Care Date: 2009-06-01 Impact factor: 17.152
Authors: Qi Sun; Rob M van Dam; James B Meigs; Oscar H Franco; Christos S Mantzoros; Frank B Hu Journal: Diabetes Date: 2009-12-03 Impact factor: 9.461